Spcs Administration 200 Ver 4.1 (svensk) [PORTABLE] Download Pc 🚩
Spcs Administration 200 Ver 4.1 (svensk) Download Pc
In Portugal still in an immature stage, interesting to prove its metabolizability to date the Real Pharmacy Society is planning the present study. In this pilot study, in view of get a first knowledge, we have selected to carry out the repaglinide pharmacokinetic analysis with flucloxacillin as a sensitive marker. The time of repaglinide administration in relation with flucloxacillin was scheduled in order to allow an easy connection to the circadian clock, as this final will be the real objective of our study. Studies will be performed at 9 am and 1 pm with a 24-hours interval between 2 repaglinide administrations (overnight). The objective is to carry out a time-dependant pharmacokinetic analysis.
For the final approval of the project, we will carry out a repaglinide pharmacokinetic analysis in real life, approved by the responsible authorities in Portugal. Thus, the innovative approach of this PhD thesis is the application of chronobiology to pharmacokinetics in a pharmacokinetic model in a real-life setting. This study will be used to get a first knowledge on flucloxacillin as a sensitive marker for the time of repaglinide administration to get a first knowledge.
objective: To compare the time-dependant pharmacokinetic effects of a circadian rhythm on repaglinide, after administration at 6 am and 12 pm, based on a chronodisruption or its normalization by a Mediterranean diet.
Materials and methods: After approval of the Ethics Committee and written informed consent, 18 healthy volunteers were assigned at random to receive repaglinide at 6 am or 12 pm in a randomized crossover trial. Plasma levels of repaglinide and its metabolites were measured at intervals up to 23 hours after administration, using a validated LC-MS/MS method. Plasma OA levels were determined by an established and validated LC-MS/MS method. Each volunteer consumed a Standard Mediterranean Diet for four days. Then for six days they took a similar diet low in OA (one tablespoon of olive oil instead of the normal 3 tablespoons a day). After three weeks of either dietary treatments, the volunteers crossed over to another dietary treatment for an additional three weeks. The dietary treatments were given in a randomized double-blind crossover design and each dietary treatment was separated by a washout period of at least three weeks.
Results: Metabolization of repaglinide was dose-independent and independent of circadian rhythm. Pharmacokinetic profiles were generally similar for both dosing times. However, significant differences between the two treatments were observed in the mean area under the time-concentration curve from 0 to 24 hours (AUC(0-24)), total body clearance (Cl/F) and fasting plasma glucose (FPG) levels. Repaglinide was more rapidly absorbed when given at 6 am (15% faster than 12 pm, p<0.
Phase I clinical trial of DWJ211, a novel Lm5sia6-targeting vaccine, has been conducted in healthy Korean subjects. Sixty healthy adult volunteers were divided into 3 groups; 50 mg DWJ211 group, 100 mg DWJ211 group, and the placebo group. After 14 days, the all subjects who received a high dose (200 mg DWJ211) were discontinued. Blood samples of subjects in the placebo group were collected up to 24 hours before and after the administration of DWJ211. Safety and tolerability were evaluated by adverse events (AEs), 12-lead electrocardiograms, vital signs, physical examinations, and laboratory clinical tests.
The present study was conducted to evaluate the potential of DWJ211, a Lm5sia6-targeting vaccine, as a vaccine for COVID-19 (clinical trials registration: NCT04312009). Phase I clinical trial of DWJ211 in healthy adults has been conducted in Korea. Adult healthy volunteers were divided into 3 groups: placebo group, low dose group (50 mg DWJ211), and high dose group (200 mg DWJ211). After 14 days, placebo group was discontinued. Blood samples of subjects in low and high dose groups were collected up to 24 hours before and after the administration of DWJ211. Safety and tolerability were evaluated by adverse events (AEs), 12-lead electrocardiograms, vital signs, physical examinations, and laboratory clinical tests.
We initiated a randomized, placebo-controlled clinical trial in 150 patients to evaluate the effect of daily (for 3 months of the year, starting one week after acute myocardial infarction with coronary artery stenting) oral administration of 15 Cabernet Sauvignon grape polyphenol concentrate (a dietary supplement with a concentration of polyphenols 2 mg/ml). We measured the change in TMAO concentration, the level of oxidative stress, as well as the number of cardiovascular events during the year in patients after acute myocardial infarction with ST segment elevation (STEMI). Secondary endpoint: was to measure the degree of progression of coronary atherosclerotic plaques according to the SYNTAX scale.